Belite Bio Inc ADR Dossier - Source-backed chat

Belite Bio Inc ADR

BLTENASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)-0.49

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $169.82Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $6.8B

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Belite Bio is a high-conviction clinical-stage biopharmaceutical company poised to commercialize the first-ever approved treatment for Stargardt disease type 1 (STGD1). The company completed its rolling NDA submission to the FDA for its lead candidate, tinlarebant, on June 12, 2026, backed by robust Phase 3 DRAGON trial data showing a 35.7% reduction in retinal lesion growth. With an exceptionally strong cash and investments position of $798.6 million as of March 31, 2026 (comprising $276.4 million in cash and cash equivalents and $522.2 million in U.S. treasuries), Belite Bio is fully funded for its planned U.S. commercial launch and the continuation of its Phase 3 PHOENIX trial in Geographic Atrophy (GA).

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$185.00

Mean target$214.00

High · most bullish analyst$270.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$132.0015%

The FDA issues a Complete Response Letter (CRL) or Refusal to File, demanding a second Phase 3 trial for STGD1 approval due to reliance on a single study or concerns over the lesion growth primary endpoint. This delays commercialization by 2-3 years, significantly increasing cash burn and depressing the stock price.

Base CaseCentral scenario

$214.0060%

Matches the consensus mean

The FDA accepts the NDA and approves tinlarebant for STGD1 in early 2027 based on the single Phase 3 DRAGON trial. Commercial launch begins in 2027 with steady uptake, supported by the company's $300 million launch budget. The PHOENIX trial continues toward its 2027 completion with supportive interim safety/efficacy data in H2 2026.

Bull CaseUpside scenario

$266.0025%

The FDA accepts the NDA and grants priority review, leading to approval in Q1 2027 without requiring a second Phase 3 trial. Tinlarebant achieves rapid market penetration in the U.S. (targeting 53,000 STGD1 patients) at orphan drug pricing (~$350,000/year). Additionally, the PHOENIX trial interim readout in H2 2026 shows strong efficacy in Geographic Atrophy, unlocking a multi-billion dollar dry AMD market.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Completed rolling NDA submission for tinlarebant in STGD1 on June 12, 2026, targeting a massive unmet medical need with no currently approved therapies.
Robust Phase 3 DRAGON trial data demonstrating a statistically significant 36% reduction in atrophic lesion growth rate (p-value = 0.0033).
Exceptional balance sheet strength with $798.6 million in cash, cash equivalents, and U.S. Treasury securities as of March 31, 2026, providing a multi-year runway through commercial launch.
Broad regulatory support including Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations in the U.S., and Orphan Drug status in the U.S., Europe, Japan, and Switzerland.

Key Investment Risks

Regulatory risk associated with seeking FDA approval based on a single Phase 3 clinical trial (DRAGON).
Potential rejection or skepticism from European regulators (CHMP) regarding the use of lesion growth rate as a primary endpoint.
Commercial execution risk as a clinical-stage company transitioning to its first product launch.

Thesis Invalidation Triggers

FDA issuance of a Refusal to File or a Complete Response Letter requiring a second Phase 3 trial for STGD1.
Failure of the PHOENIX Phase 3 trial interim analysis in Geographic Atrophy to show clinical efficacy or acceptable safety.
Significant delays in the regulatory timeline or commercial launch preparations.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.